C4X Discovery continues its progress with the signing of an exclusive global license with AstraZeneca.
C4X Discovery Holdings plc, a pioneering Drug Discovery company, confirms that Clive Dix, Chief Executive Officer of C4XD has stepped into the role of Interim Chair of the UK Vaccine Taskforce, the group set up by the Government to lead UK efforts to find and manufacture a COVID-19 vaccine. The Government will set out arrangements … Continued
Calculus Capital portfolio company C4X Discovery Holdings plc has teamed up with fellow UK-based biopharma, PhoreMost, to look for treatments for Parkinson’s Disease and other ‘undruggable’ diseases. The pair will take potentially useful compounds already identified by C4X’s Taxonomy 3 platform and run them through PhoreMost’s SITESEEKER screening platform. That data can then be exploited by … Continued
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc, a pioneering drug discovery company, to validate targets and develop next-generation oncology drugs. The partnership aims to validate the novel synthetic lethal … Continued
C4X recently announced that their C4X3256 programme has been awarded a grant from the National Institute on Drug Abuse (NIDA, a division of National Institute of Health (NIH)). The grant of approximately $480k will support the pre-clinical development of C4X3256 in cocaine use disorder, an additional addiction indication with high unmet need. Recently licensed to Indivior, C4X3256, an … Continued